{"id":19166,"date":"2026-06-10T23:00:00","date_gmt":"2026-06-10T21:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=063f1ba5066726ea31972c2800866fdb"},"modified":"2026-06-10T23:00:00","modified_gmt":"2026-06-10T21:00:00","slug":"karl-storz-announces-fda-clearance-for-rubina-lens-for-open-surgery","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=19166","title":{"rendered":"KARL STORZ Announces FDA Clearance for Rubina Lens for Open Surgery"},"content":{"rendered":"

\nPowerful technology lets surgeons incorporate NIR\/ICG imaging into open procedures<\/i><\/b><\/p><\/a><\/a><\/a><\/a>

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ, a global leader in endoscopic and minimally invasive surgical technology, has received FDA clearance for the Rubina\u2122 Lens exoscope for open surgery, broadening the company\u2019s near-infrared (NIR) imaging ecosystem across open and minimally invasive procedures in the United States.<\/p>

\nThe digital, camera\u2011based Rubina\u2122 Lens exoscope displays a real\u2011time, magnified 4K image of the surgical field on a monitor. With the ability to switch into NIR imaging using indocyanine green (ICG), the Rubina\u2122 Lens exoscope helps reveal important information that cannot be seen with the naked eye, supporting more informed decision\u2011making during open surgery.<\/p>

\n\u201cThe Rubina Lens extends real-time fluorescence visualization into open surgery, integrating seamlessly with existing OR platforms,\u201d said Fernando Morales, Vice President, Surgical & OR Integration, KARL STORZ United States. \u201cIt enables surgeons to incorporate NIR imaging into open procedures without unnecessary complexity or workflow burden.\u201d<\/p>

\nThe Rubina\u2122 Lens is indicated for real-time tissue perfusion assessment, lymphatic mapping, and breast surgery and is designed for use in any open surgical procedure where NIR imaging with ICG may support intraoperative decision making. As with the fully endoscopic version, Rubina\u2122 Lens gives the surgeon several options for viewing the NIR\/ICG fluorescence imaging signal. By integrating directly with existing KARL STORZ IMAGE1 S\u2122 Rubina\u2122 imaging platforms, the Rubina\u2122 Lens enables surgical teams to expand fluorescence capabilities without additional capital investment. The exoscope can be used handheld or mounted on a holding arm, providing flexibility across surgical settings.<\/p>

\nAlready approved for use in markets outside the United States, the Rubina\u2122 Lens exoscope brings proven NIR imaging technology to US surgeons performing open procedures, addressing the need for consistent visualization across surgical approaches. To learn more about Rubina\u2122 Lens for open surgery and other KARL STORZ NIR\/ICG imaging solutions, visit karlstorz.com.<\/p>

\nAbout KARL STORZ<\/span><\/p>

\nKARL STORZ is an innovative leader in endoscopic technology and surgical imaging across virtually all surgical specialties. The company\u2019s advanced imaging and integration solutions are designed to enhance collaboration to improve clinical efficiency and outcomes inside the hospital and other sites of care. Based in Germany, KARL STORZ is a global family-owned company that designs, engineers, manufactures, and markets all its products with an emphasis on visionary design, precision craftsmanship, and clinical effectiveness. For more information, visit www.karlstorz.com<\/a>.<\/p> Contacts<\/b>

\nMedia contact:<\/span>Susan Mancia\nMarketing Communications\nKARL STORZ North America\n657-385-5285<\/p>","protected":false},"excerpt":{"rendered":"

Powerful technology lets surgeons incorporate NIR\/ICG imaging into open proceduresEL SEGUNDO, Calif.–(BUSINESS WIRE)–KARL STORZ, a global leader in endoscopic and minimally invasive surgical technology, has received FDA clearance for the Rubina\u2122 Len…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-19166","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/19166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19166"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/19166\/revisions"}],"predecessor-version":[{"id":19167,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/19166\/revisions\/19167"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}